** Analysts expect Indian drugmaker Dr Reddy's Laboratories REDY.NS to report near 14% rise in Q4 consol net PAT, rev to grow 18%, per data compiled by LSEG

** REDY's reported 2.3% rise in Q3 profit, and 36.5% in Q4 a year ago

** Jan-March qtr results to be helped by new drug launches in oncology and other chronic therapy areas, analysts say

** India business to see 15% YoY growth on incremental sales from acquired vaccine business from Sanofi India SANO.NS, says brokerage HDFC Securities

** Stock trading flat on the day vs 1.2% fall in the benchmark Nifty 50 index .NSEI

** REDY shares fell 17.6% in the Jan-March quarter, snapping eight straight quarterly gains, on Trump tariff woes

** REDY down ~2.6% this week, snapping three weeks of gains

** REDY among 8 stocks on 20-member pharma index rated "hold", rest, including rival Cipla CIPL.NS rated "buy" or higher- data compiled by LSEG

** REDY's down ~17% YTD while Nifty Pharma index .NIPHARM is down ~10.2%

($1 = 85.5200 Indian rupees)

(Reporting by Anuran Sadhu in Bengaluru)

((Anuran.Sadhu@thomsonreuters.com; +91 8697274436;))